Abstract:
Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I), wherein the substituents are as defined herein, which are useful as therapeutic agents.
Abstract:
The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.
Abstract:
La presente invención se dirige a agentes novedosos, potentes y selectivos, los cuales son agonistas o antagonistas del uno omás de los receptores individuales de la familia del receptor S1P. Los compuestos de la presente invención son útiles como terapéuticos para tratar condiciones médicas asociadas con agonismo o antagonismo de los receptores individuales de la familia del receptor S1P.
Abstract:
The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual rece ptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or a ntagonism of the individual receptors of the S1P receptor family.
Abstract:
Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
Abstract:
La presente invención esta dirigida a agentes nuevos, potentes y selectivos, los cuales son agonistas o antagonistas de uno o más de los receptores individuales de la familia de receptores S1P. Los compuestos de la invención son usados como terapia en el tratamiento de condiciones médicas asociadas con el agonismo o antagonismo de los receptores individuales de la familia de receptores S1P.